# US 2020/0370130 A1 · Morphometric genotyping of cells using optical tomography for detecting tumor mutational burden

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0370130 A1
- Document ID: US20200370130A1
- Status: Published application
- Kind: A1
- Application number: 16/959,806
- Filed: 2019-01-04
- Published: 2020-11-26
- Earliest claimed: 2018-01-05
- Assignees: Visiongate, Inc.
- Applicants: Visiongate, Inc.
- Inventors: Daniel J. Sussman; Michael Meyer G. Meyer; Laimonis Kelbauskas; Alan C. Nelson; Randall Mastrangelo
- Web page: https://patentgrep.com/patent/US20200370130A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/50: Mutagenesis
- G16B 40/20: Supervised data analysis
- C12Q 2525/301: Hairpin oligonucleotides
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2800/50: Determining the risk of developing a disease
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method to develop one or more morphometric classifiers to identify a tumor mutation burden (TMB). The method provides a non-invasive method of characterizing TMB that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.

## Claims

### Claim 1

A method for developing one or more morphometric classifiers to identify a tumor mutation burden (TMB), the method comprising:
deriving selected clones from transduced cells;
analyzing the selected clones for MLH1 expression to screen for those with levels equivalent to a parental cell line;
expanding the selected clones in culture;
harvesting the selected clones;
determining the TMB level for the harvested clones;
analyzing the selected clones on a 3D microscopy optical tomography system; and
comparing the selected clones to a set of control cell lines.

### Claim 2 (depends on 1)

The method of claim 1 wherein the set of control cell lines comprise parental NCI-H23 and clones expressing the scrambled shRNA.

### Claim 3 (depends on 1)

The method of claim 1 wherein the act of analyzing generates a plurality of morphometric biosignatures for each cell.

### Claim 4 (depends on 3)

The method of claim 3 further comprising using low and high TMB as a ground truth for developing a cell classifier for each cell in an isogenic cell line and determining the area of ROC for each cell classifier.

### Claim 5 (depends on 4)

The method of claim 4 further comprising defining a score that matches the ground truth for each cell in the isogenic cell line.

### Claim 6 (depends on 2)

The method of claim 2 further comprising producing a score that closely matches a ground truth.

### Claim 7 (depends on 1)

The method of claim 1 wherein analyzing the selected clones comprises using an Adaptively boosted logistic regression algorithm to define a set of projection axes used through the logic function to produce a score ranging from 0 to 1.

### Claim 8 (depends on 7)

The method of claim 7 wherein the Adaptively boosted logistic regression algorithm is iterated with successive trials using by weighting each observation by the differential between ground truth and the current score to adaptively converge on a solution that gradually a wider set of the cellular characteristics into the solution.

### Claim 9 (depends on 1)

The method of claim 1 wherein analyzing the selected clones comprises using a Random Forest algorithm to produce classifier using a non-parametric assumption for the feature distribution.

### Claim 10 (depends on 9)

The method of claim 9 further comprising assessing classifier discrimination by pruning a potential set of feature trees to optimize the discriminant.

### Claim 11 (depends on 1)

The method of claim 1 further comprising using the area under an ROC curve aROC to judge classifier efficacy wherein area under the receiver operating characteristic curve, or aROC, is calculated by computing the integral of the ROC curve, which represents the overall performance of a binary classifier output in terms of classification sensitivity and specificity.

### Claim 12 (depends on 1)

The method of claim 1 further comprising establishing thresholds to use with the classifier score to create a binary output that correlates with the ground TBM with high accuracy.

### Claim 13 (depends on 1)

The method of claim 1 further comprising producing a numeric score representing the probability for a cell to belong to the target class.

### Claim 14 (depends on 13)

The method of claim 13 further comprising separating target from non-target cells by further making the scores binary by applying a threshold to the scores distribution.

### Claim 15 (depends on 11)

The method of claim 11 wherein the threshold value will be determined to provide an accuracy of 0.95 or higher for separating cells with low TMB from those with high TMB.

### Claim 16 (depends on 15)

The method of claim 15 further comprising determining TMB data from genomic profiling performed using either whole exome sequencing or targeted exome sequencing utilizing NGS or target gene panels.

### Claim 17

A method for training one or more morphometric classifiers to identify a tumor mutation burden (TMB), the method comprising:
deriving selected clones from transduced cells;
analyzing the selected clones for MLH1 expression to screen for those with levels equivalent to a parental cell line;
expanding the selected clones in culture;
harvesting the selected clones;
determining the TMB level;
analyzing the selected clones on a 3D microscopy optical tomography system;
generating a plurality of morphometric biosignatures for each selected clone;
using an Adaptively boosted logistic regression algorithm to define a set of projection axes used through the logic function to produce a score ranging from 0 to 1, or a Random Forest algorithm to produce classifier using a non-parametric assumption for the feature distribution;
and
comparing the selected clones to a set of control cell lines.

### Claim 18 (depends on 17)

The method of claim 17 wherein the set of control cell lines comprise parental NCI-H23 and clones expressing the scrambled shRNA.

### Claim 19 (depends on 17)

The method of claim 17 wherein the act of analyzing generates a plurality of morphometric biosignatures for each cell.

### Claim 20 (depends on 17)

The method of claim 17 further comprising using low and high TMB as a ground truth for developing a cell classifier for each cell in an isogenic cell line and determining the area of ROC for each cell classifier.

### Claim 21 (depends on 17)

The method of claim 17 further comprising using the area under an ROC curve aROC to judge classifier efficacy wherein area under the receiver operating characteristic curve, or aROC, is calculated by computing the integral of the ROC curve, which represents the overall performance of a binary classifier output in terms of classification sensitivity and specificity.

### Claim 22 (depends on 17)

The method of claim 17 further comprising establishing thresholds to use with the classifier score to create a binary output that correlates with the ground TBM with high accuracy.

### Claim 23 (depends on 17)

The method of claim 17 further comprising producing a numeric score representing the probability for a cell to belong to the target class.

### Claim 24 (depends on 17)

The method of claim 17 further comprising separating target from non-target cells by further making the scores binary by applying a threshold to the scores distribution.

### Claim 25

A method of treating a malignancy in a human subject using immunotherapy comprising:
analyzing 3D images of cells based on pseudo-projections obtained from a specimen obtained from a subject;
operating a biological specimen classifier to identify cells from the specimen as normal or abnormal;
determining a TMB score from for each of the abnormal cells;
applying a predetermined threshold to the TMB score;
when cancer is found, then administering surgical procedures to remove the cancer lesion;
when the TMB score exceeds the predetermined threshold, then triaging the subject as a candidate for conducting immunotherapy by administering an immunomodulating agent to a human subject over a predetermined time period to assist the immune system of the human subject in eradicating cancerous cells.

### Claim 26 (depends on 25)

The method of claim 25 wherein the immunomodulating agent comprises a drug selected from the group consisting of a chimeric immunoreceptor, a prostacyclin analog, iloprost, a chimeric antigen receptor (CAR) for T-cells, Vorinostat, HDAC inhibitors, cholecalciferol, calcitriol and combinations thereof.
